Compounded vs Brand-Name Medications. What's actually different.

Quick comparison at a glance

The short version — here is how FDA-Approved Medications and Compounded Medications stack up on the questions most patients ask before picking one.

FDA-Approved Medications

• Drug class: Finished drug products
• Brand names: Brand-name drugs and FDA-approved generics
• Mechanism: Manufactured to FDA-approved specifications under regulated manufacturing practices (cGMP). Approval requires demonstration of safety and efficacy in adequate clinical trials.
• Dosing: Specific doses approved by the FDA based on clinical trial data. Every FDA-approved drug has a prescribing information document (the package insert) that describes approved indications, doses, safety information, and contraindications.
• Half-life: Characterized in the FDA prescribing information.
• FDA indication: Each FDA-approved drug has one or more FDA-approved indications determined by the clinical trials submitted at approval.
• FDA status: Approved. Subject to ongoing post-market surveillance and adverse event reporting.
• Manufacturer: Pharmaceutical manufacturers inspected and authorized by the FDA.
• Common side effects: Well-characterized in clinical trials and post-market surveillance. Included in the prescribing information.
• Typical price range: Varies widely. Brand products can be expensive; FDA-approved generics are typically much cheaper than brand and are rated AB (bioequivalent) to the reference product.

Compounded Medications

• Drug class: Preparations compounded by licensed pharmacies under valid prescriptions
• Brand names: (Custom compounded preparations)
• Mechanism: Prepared using bulk active pharmaceutical ingredient (API) sourced from FDA-registered manufacturing facilities (for legitimate pharmacies), combined with excipients appropriate to the dosage form. Subject to state pharmacy rules and, for 503B outsourcing facilities, additional FDA oversight.
• Dosing: Custom prepared for an individual patient per prescription. Dose ranges depend on the prescribing physician's clinical judgment rather than a single FDA-approved dosing schedule.
• Half-life: Same as the parent active ingredient.
• FDA indication: None — compounded medications are not FDA-approved and do not carry an FDA-approved indication. Prescribed off-label at physician discretion.
• FDA status: NOT FDA-approved. Legal to compound under federal law (503A/503B) and state pharmacy law, but not independently evaluated by the FDA for safety, efficacy, or manufacturing consistency.
• Manufacturer: Licensed compounding pharmacies, either 503A (patient-specific) or 503B (outsourcing facilities under stricter oversight).
• Common side effects: Expected to mirror the active ingredient's profile, but specific compounded formulations have not been independently evaluated.
• Typical price range: Typically much lower than brand-name products for the same active ingredient. Not covered by insurance in most cases.

What pharmacy compounding actually is

Pharmacy compounding is the custom preparation of a medication by a licensed pharmacist, in response to a valid prescription from a licensed prescriber, for an individual patient. It has existed for as long as pharmacy has existed — traditionally it was used to prepare a pediatric dose from an adult tablet, remove an allergen from a formulation, combine multiple ingredients, or prepare a medication in a form the patient could take (liquid instead of tablet, transdermal instead of oral, etc.).

Under federal law, compounding falls into two categories:

• Section 503A pharmacies. Traditional compounding pharmacies that prepare medications for specific individual patients based on a prescription. Regulated primarily at the state level.
• Section 503B outsourcing facilities. Larger facilities that can prepare compounded medications in batches under stricter FDA oversight, registered with the FDA as outsourcing facilities.

Both are legal and both serve legitimate clinical purposes. Neither is the same thing as FDA-approved drug manufacturing, and compounded products are not subject to the same pre-market approval or post-market surveillance as FDA-approved drugs.

Why compounding is legal during drug shortages

Under section 503A of the FDCA, compounding pharmacies are generally prohibited from preparing medications that are "essentially copies" of commercially available FDA-approved drugs. The rule exists to prevent compounding from becoming a workaround for the FDA approval process.

However, when the FDA places a drug on its official shortage list, the "essentially a copy" prohibition is relaxed. Compounding pharmacies can prepare the molecule during an active shortage, from legitimate API sourced from FDA-registered facilities, to fill the gap created by the unavailability of the brand-name product.

This is why compounded semaglutide and compounded tirzepatide became widely available — both drugs spent significant time on the FDA shortage list as demand for brand Wegovy, Ozempic, Zepbound, and Mounjaro exceeded supply. When a drug comes off the shortage list, the legal basis for routine mass compounding of that molecule narrows again.

What FDA approval actually buys you

Understanding what the FDA approval label means helps clarify what you get with a brand product and what you don't get with a compounded alternative:

• Phase 1, 2, and 3 clinical trials. FDA approval requires data showing the drug is safe and effective for its indication in large numbers of patients. For major conditions, this typically means thousands of patients studied over years.
• Manufacturing inspection. FDA inspectors review the manufacturing facility, raw materials, quality control, and documentation. The facility must comply with current Good Manufacturing Practices (cGMP).
• Standardized labeling. The FDA reviews and approves the prescribing information (package insert), including indications, dosing, contraindications, and safety warnings.
• Post-market surveillance. After approval, manufacturers must report adverse events, maintain pharmacovigilance programs, and respond to safety signals.
• Bioequivalence (for generics). FDA-approved generic drugs must demonstrate bioequivalence to the reference product — same active ingredient at the same rate and extent of absorption.

None of these are guaranteed for compounded medications. A reputable compounding pharmacy may source legitimate API, test for potency and sterility, and maintain quality standards — but those are voluntary commitments, not regulatory requirements with FDA enforcement.

When compounded medications actually make sense

Compounded medications have legitimate clinical uses. The honest list:

1. 1During FDA-declared drug shortages. The main reason compounded GLP-1 medications became widely available.
2. 2For patients with documented allergies to inactive ingredients in FDA-approved products — compounding allows the same active ingredient in a different vehicle.
3. 3For custom doses or combinations not commercially available, when a specific dose is clinically needed.
4. 4For alternative routes of administration (topical for a drug only available as oral, or sublingual for a drug only available as injectable).
5. 5For pediatric populations when only adult formulations exist commercially.
6. 6For research peptides and drugs with no FDA-approved finished product (BPC-157, TB-500, sermorelin, etc.), where the compounded option is the only legal path to access.

Red flags to watch for

Not all compounding operations are reputable. Red flags that a telehealth platform or pharmacy may be cutting corners:

• The platform will not tell you which specific compounding pharmacy fills your prescriptions.
• The pharmacy cannot or will not disclose API sourcing (specifically, whether API comes from FDA-registered manufacturing facilities).
• No documentation of third-party potency and sterility testing.
• Products labeled as "salt forms" or alternative chemistry (especially for tirzepatide — this has been specifically flagged by the FDA).
• Marketing claims that compounded versions are "equivalent" or "identical" to brand products (they have not been evaluated for equivalence).
• Marketing claims that compounded hormones are "more bioidentical" or "safer" than FDA-approved hormones.
• A prescribing process that does not involve real physician review — if a pharmacy or platform will send you a compounded prescription without meaningful clinical evaluation, that's a problem.

Who tends to do better on each

There is no universally better option — only a better fit for your specific clinical picture, history, budget, and preferences. A licensed physician reviews all of those before prescribing. Here is the honest framing on who typically does better on each.

FDA-Approved Medications

FDA-approved medications are the default standard of care for most conditions. When an FDA-approved product exists for a patient's condition at an appropriate dose, it is typically the first choice because of the regulatory safety net and the clinical evidence behind it.

Compounded Medications

Compounded medications are appropriate in specific situations: during FDA-declared shortages of brand products, for patients with documented allergies to inactive ingredients in commercial products, for custom doses not commercially available, and when a licensed physician determines that the compounded option fits a specific clinical need.